Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis

Lichter, K.; Krause, Danielle; Xu, Jingwen; Tsai, Sung Huang Laurent; Hage, Camille; Weston, Erica; Eke, Ahizechukwu C.; Levinson, Kimberly

doi:10.1097/ogx.0000000000000822

Cited by 13 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Notably, none of the vaccine HPV types were detected in the women in the vaccinated group whose disease recurred, whereas types 16, 11 and 18-alone or, more frequently, in association with otherswere detected in 9 women in the unvaccinated group [93]. Further data on the significance and relevance of HPV vaccination as an adjuvant therapy for gynecological diseases came recently from a retrospective study conducted by Sand and colleagues in Denmark [94], from the works of Petrillo and colleagues [95], and Bogani and colleagues [96] in Italy, from the research done by Del Pino and colleagues in Spain [97], and from two systematic reviews and meta-analyses [98,99].…”

Section: Vaccination In Women Treated For Precancerous Cervical Lesionsmentioning

confidence: 91%

Towards the elimination of cervical cancer: HPV epidemiology, real-world experiences and the potential impact of the 9-valent HPV vaccine

Prandi¹,

Cocchio²,

Fonzo³

et al. 2021

EJGO

View full text Add to dashboard Cite

This review aims to describe the biology of human papillomavirus (HPV), the development of the related vaccine, real-life experiences from the perspective of the WHO's call on the elimination of cervical cancer, the vaccine's use as an adjuvant to treatments for HPV-related disease, and the international scientific societies' guidelines on HPV vaccination. A systematic review was conducted, also for the specific purpose of assessing the efficacy, immunogenicity and safety of the 9-valent HPV vaccine (the latest to become available). Data sources and study selection methods: PubMed was the primary source of data for this review, while additional information, such as scientific society guidelines, was found by directly searching the web. Publications were eligible if they had at least one result relating to the immunogenicity, safety and efficacy or effectiveness of HPV vaccines. Tabulation, integration and results: The search in the database for this systematic review yielded 266 records, none of which was a duplicate. A first screening procedure excluded 228 publications. Of the remaining 38 potentially eligible publications, 26 were ultimately included in the systematic review. Conclusion: While progress in vaccine development has added more tools to HPV vaccination programs, real-word studies have started to show the benefits of mass vaccination campaigns using bivalent and quadrivalent vaccines. National vaccination programs have also been a testing ground for gender-neutral vaccination-a strategy on which unanimous consensus may not still be lacking, but which undeniably responds to clinical and ethical needs. Much the same can be said of post-treatment vaccination-a relatively new, but promising practice that will certainly have a role in achieving the elimination of cervical cancer.

show abstract

Section: Vaccination In Women Treated For Precancerous Cervical Lesionsmentioning

confidence: 91%

Towards the elimination of cervical cancer: HPV epidemiology, real-world experiences and the potential impact of the 9-valent HPV vaccine

Prandi¹,

Cocchio²,

Fonzo³

et al. 2021

EJGO

View full text Add to dashboard Cite

show abstract

“…Notably, DC vaccines loaded with autologous tumor lysates were used in a cohort of completely resected liver metastasis of colon adenocarcinoma; this cohort showed fewer and later relapses in the vaccine arm, suggesting that the strategy might play a role in more disseminated disease (143). In addition, recent data show that the post-treatment adjuvant HPV vaccine's effectiveness contributes to decreased risk of recurrence of HPV-associated lesions, such as cervical and anal intraepithelial neoplasia (144)(145)(146).…”

Section: Cancer Vaccines As Adjuvant Therapies After Curative Treatmentmentioning

confidence: 99%

Vaccines for immunoprevention of cancer

Enokida¹,

Moreira²,

Bhardwaj³

2021

Journal of Clinical Investigation

View full text Add to dashboard Cite

“…In einer Metaanalyse mit systematischem Review konnte gezeigt werden, dass durch die adjuvante HPV-Impfung das Rezidivrisiko einer CIN 1-3 signifikant von 9,7 auf 6,3 % absolut gesenkt werden kann (relatives Risiko 0,67; 95 %-KI 0,52-0,85). Dies entspricht einer "number needed to treat" von 29 [4]. Auswertungen von Studienpopulationen aus den Phase-III-Zulassungsstudien beider HPV-Impfstoffe zeigen einen Schutz vor Wiedererkrankung bei Frauen, die während ihrer HPV-Infektion, aber vor der CIN-Erkrankung geimpft wurden.…”

Section: Merkeunclassified